Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica…. Current Pharmaceutical Design 2011

Document identifier
CEI-BR-101
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Stupnisek M, Suran J, Barisic I, Dzidic S, Prkacin I
Title
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Source
Current Pharmaceutical Design
Year
2011
Volume, issue, pages
17(16):1612–1632
Digital object identifier
10.2174/138161211796196954
PubMed identifier
21548867
Record type
Journal article
Institute identifier
CEI-BR-101

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: BPC-157Compound monograph
1 citing document.

§1.3Subject tags

bpc-157 preclinical review

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.